Clinical trials: Neurotrophic Keratitis
Neurotrophic Keratitis, Neurotrophic Keratopathy
Open-label Trial to Evaluate Efficacy and Safety of rhNGF on Corneal Thickness Via AS-OCT in Neurotrophic Keratitis
Primary Objective: To assess the efficacy of cenegermin-bkbj (20 mcg/mL) ophthalmic solution on overall corneal thickness via AS-OCT in patients with stage 3 neurotrophic keratitis with respect to change from baseline at weeks 4…
- Conditions
- Neurotrophic Keratitis, Neurotrophic Keratopathy, Corneal Ulcer
- Trial name
- IMAGO (NCT06411145)
- Testing
- OXERVATE® 0.002%
- Sponsor
- Dompé Farmaceutici S.p.A
Dry Eye
Real-World Assessment of VEVYE® for Short-Term Symptom and Sign Improvement of Dry Eye Disease in a Neuro-Ophthalmology Clinic: A 6-Month Prospective Observational Study
patients from a Neuro Ophthalmology who have dry eye, some of which have neurotrophic keratitis are being analyzed after treatment with Vevye
- Trial name
- NCT07566975
- Testing
- Cyclosporine ophthalmic solution 0.1%
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Neuro-Ophthalmology of Texas
Neurotrophic Keratopathy
Autologous Platelet-rich Plasma (APRP) in the Treatment of Neurotrophic Keratopathy
Neurotrophic keratopathy (NK) is a condition where the cornea loses its capacity to feel pain and touch. This causes a decrease in the production of certain substances that maintain the integrity of the corneal epithelium (the…
- Trial name
- NCT04604834
- Testing
- PFAT first, APRP first
- Where
- Mexico
- Volunteers
- 39 people
- Sponsor
- Universidad Autonoma de Nuevo Leon
Corneal Epithelial Defect
Treatment of PED With AMT and Autologous Serum
Patients with persistent corneal epithelial defects who have not responded to conventional therapy will be randomized to treatment with either amniotic membrane transplantation or autologous serum 20%.
- Trial name
- NCT00238862
- Testing
- Amniotic membrane transplantation, Autologous serum/BSS 20%
- Where
- Saudi Arabia
- Volunteers
- 180 people
- Sponsor
- King Khaled Eye Specialist Hospital
Diabetic Retinopathy, Neurotrophic Keratitis
An Investigator-Initiated Study to Assess the Association of Diabetic Retinopathy Severity Scale (DRSS) With Level of Decreased Corneal Sensitivity
Evaluate the association between level of decreased corneal sensitivity and diabetic retinopathy severity scale
- Trial name
- Assess (NCT05566717)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Medical Center Ophthalmology Associates
Neurotrophic Keratopathy
A Clinical Trial to Asses Efficacy and Safety of Cord Blood Eye Drops in Neurotrophic Keratopathy
This is a multicenter, randomized, open-label, two-arms phase I/II, clinical trial, in which 42 patients will be enrolled with the principal objective to evaluate the efficacy through changes in lesion size and, secondary, to…
- Trial name
- NCT03084861
- Testing
- Cord Blood Eye Drops, Conventional treatment
- Where
- 10 sites in Spain
- Volunteers
- 9 people
- Sponsor
- Banc de Sang i Teixits
Corneal Ulcer, Neurotrophic Corneal Ulcer
Topical Insulin in Neurotrophic Keratopathy After Diabetic Vitrectomy
Various treatment options have been proposed in managing NK such as preservative-free lubrication (PF-L), withdrawal of epitheliotoxic medication, prophylactic antibiotics, applying of bandage contact lenses, using…
- Conditions
- Corneal Ulcer, Neurotrophic Corneal Ulcer, Diabetes Mellitus
- Trial name
- NCT05940376
- Testing
- rapid acting insulin
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Benha University
Rare Diseases, Aniridia
Validation of Human Drugs Target of Repurposed Drugs and Novel Therapies
The cross-sectional observational clinical study related to rare eye diseases is a multi-center study in which the hypothesis is that neurokinin 1 receptor and/or substance P expression is increased in REDs associated with…
- Conditions
- Rare Diseases, Aniridia, Neurotrophic Keratopathy, Limbal Stem Cell Deficiency
- Trial name
- NCT06412718
- Volunteers
- 274 people, healthy volunteers welcome
- Sponsor
- IRCCS Ospedale San Raffaele
Neurotrophic Keratitis
DEFENDO Long Term Follow-up Study in Stage 1 NK Patients
Primary Objective To evaluate the long-term safety and efficacy (healing) of OXERVATE® 0.002% (20 mcg/mL) cenegermin-bkbj ophthalmic solution in Stage 1 neurotrophic keratitis (NK) patients who enrolled in the DEFENDO study.
- Trial name
- NCT05552261
- Testing
- Cenegemin in the DEFENDO Study
- Where
- 4 sites in United States
- Volunteers
- 24 people
- Sponsor
- Dompé Farmaceutici S.p.A
Neurotrophic Keratitis
Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects
This study will enroll subjects with stage 2 or 3 neurotrophic keratitis. Subjects will be randomized in a 1:1 ratio to the CSB-001 investigational treatment arm or vehicle control arm.
- Trial name
- NCT04909450
- Testing
- CSB-001 Ophthalmic Solution 0.1%, Vehicle Control
- Where
- 48 sites in United States, Canada
- Volunteers
- 131 people
- Sponsor
- Claris Biotherapeutics, Inc.
Neurotrophic Keratitis
A Phase II Study of STSP-0902 Ophthalmic Solution in Patients With Neurotrophic Keratitis
This is a Phase II, double-blind, placebo-controlled study to evaluate the safety and efficacy of STSP-0902 ophthalmic solution in patients with neurotrophic keratitis (NK).
- Trial name
- NCT06975748
- Testing
- STSP-0902 ophthalmic solution
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Staidson (Beijing) Biopharmaceuticals Co., Ltd
Dry Eye, Neurotrophic Keratitis
DOMPE -MT Neurotrophic Keratitis
TITLE: Toyos Clinic / A Phase 4 Study to Assess Longer Duration of Treatment with Cenegermin in Moderate to Severe Dry Eye-Associated Neurotrophic Keratitis
- Trial name
- NCT06947850
- Testing
- Cenegermin Ophthalmic Solution [Oxervate]
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Toyos Clinic
Sjogren's Syndrome, Dry Eye
Differences in Corneal Structure and Function in Patients With Sjogrens vs. Non-Sjogrens Dry Eye
In this study the investigators plan to enroll three groups of patients: non-Sjogren's dry eye, Sjogren's dry eye and controls. The study has the following primary goals: 1.
- Conditions
- Sjogren's Syndrome, Dry Eye, Neurotrophic Keratitis
- Trial name
- IIR (NCT06364657)
- Testing
- Eye Exam
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Corneal Disease, Neuropathy
QST for Corneal Nerve Function
This study is designed to learn more about the impact different types of stimuli, such as heat, cold and vibration, can have on ocular pain response. This is called quantitative sensory testing (QST).
- Conditions
- Corneal Disease, Neuropathy, Dry Eye Disease, Neurotrophic Keratitis
- Trial name
- NCT05758753
- Testing
- Quantitative Sensory Test
- Where
- United States
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Tufts Medical Center
Neurotrophic Keratopathy
Assessment of the Safety and Efficacy Study of RGN-259 Ophthalmic Solutions for Neurotrophic Keratopathy : SEER-1
The objective of this study is to assess the safety and efficacy of RGN-259 Ophthalmic Solution compared to placebo for the treatment of NK.
- Trial name
- NCT02600429
- Testing
- RGN-259
- Where
- 11 sites in United States
- Volunteers
- 18 people
- Sponsor
- ReGenTree, LLC
Neurotrophic Keratitis
REC 0/0559 Eye Drops for Treatment of Moderate and Severe Neurotrophic Keratitis in Adult Patients
A phase 2 study, aiming to evaluate the efficacy, safety and pharmacokinetics of REC 0/0559 in treatment of Neurotrophic Keratitis in Adult Patient in Europe and United States of America.
- Trial name
- NCT04276558
- Testing
- Udonitrectag, Vehicle
- Where
- 41 sites in United States, France and 5 more
- Volunteers
- 108 people
- Sponsor
- RECORDATI GROUP
Neurotrophic Keratitis
Study to Evaluate OXERVATE® in Patients With Stage 1 Neurotrophic Keratitis
This study is to evaluate the safety and efficacy of OXERVATE® 0.002% (20 mcg/mL) cenegermin-bkbj ophthalmic solution in patients with Stage 1 neurotrophic keratitis (NK).
- Trial name
- DEFENDO (NCT04485546)
- Testing
- cenegermin-bkbj
- Where
- 5 sites in United States
- Volunteers
- 37 people
- Sponsor
- Dompé Farmaceutici S.p.A
Persistent Corneal Epithelial Defect, Corneal Epithelial Disorders
Efficacy of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease
In this phase II randomized double-masked clinical trials, subjects with non-resolving corneal epithelial disease/defect (i.e., refractory to standard treatments for at least two weeks) will receive 8 weeks treatment of topical…
- Trial name
- NCT06919081
- Testing
- Allogeneic Bone-Marrow Derived Mesenchymal Stromal Cells Secretome, Vehicle Control
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Illinois at Chicago
Neurotrophic Keratitis
Corneal Nerves After Treatment With Cenegermin
Neurotrophic keratopathy (NK) is a condition in which patients have fewer or complete absence of nerves in the cornea, characterized by the reduced or absent corneal sensation.
- Trial name
- NCT04627571
- Testing
- Cenegermin Ophthalmic Solution [Oxervate]
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of California, Los Angeles
Ocular GVHD
The Prevalence of Hypoesthesia Related Keratitis in Ocular Graft Vs. Host Disease (GVHD) Patients
The Investigators hypothesize that the recalcitrant nature of ocular GVHD may be related to corneal nerve damage and corneal hypoesthesia.
- Trial name
- NCT04700657
- Testing
- corneal sensation test
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Indiana University